@misc{10481/78495,
year = {2022},
month = {11},
url = {https://hdl.handle.net/10481/78495},
abstract = {Background: Plasma neuronal-derived extracellular vesicles (NDEV) contain proteins of pathological, diagnostic, and therapeutic relevance.

Objective: We investigated the associations of six plasma NDEV markers with Alzheimer's disease (AD) severity, cognition and functioning, and changes in these biomarkers after Cerebrolysin (R), donepezil, and a combination therapy in AD.

Methods: Plasma NDEV levels of A beta(42), total tau, P-T181-tau, P-S393-tau, neurogranin, and REST were determined in: 1) 116 mild to advanced AD patients and in 20 control subjects; 2) 110 AD patients treated with Cerebrolysin (R), donepezil, or combination therapy in a randomized clinical trial (RCT). Samples for NDEV determinations were obtained at baseline in the NDEV study and at baseline and study endpoint in the RCT. Cognition and functioning were assessed at the same time points.

Results: NDEV levels of A beta(42), total tau, P-T181-tau, and P-S393-tau were higher and those of neurogranin and REST were lower in mild-to-moderate AD than in controls (p < 0.05 to p < 0.001). NDEV total tau, neurogranin, and REST increased with AD severity (p < 0.05 to p < 0.001). NDEV A beta 42 and P-T181-tau correlated negatively with serum BDNF (p < 0.05), and total-tau levels were associated to plasma TNF-alpha (p < 0.01) and cognitive impairment (p < 0.05). Combination therapy reduced NDEV A beta(42) with respect to monotherapies ( p < 0.05); and NDEV total tau, P-T181-tau, and P-S396-tau were decreased in Cerebrolysin-treated patients compared to those on donepezil monotherapy (p < 0.05).

Conclusion: The present results demonstrate the utility of NDEV determinations of pathologic and synaptic proteins as effective AD biomarkers, as markers of AD severity, and as potential tools for monitoring the effects of anti-AD drugs.},
organization = {United States Department of Health & Human Services},
organization = {National Institutes of Health (NIH) - USA},
organization = {NIH National Institute on Aging (NIA)	AG058252	
AG073979	
AG051848	
AG057437	
AG010483	
AG062429},
organization = {Ever Neuro Pharma GmbH (Unterach, Austria) research grant},
publisher = {IOS},
keywords = {A beta(42)},
keywords = {Alzheimer disease},
keywords = {Cerebrolysin®},
keywords = {Combination therapy},
keywords = {Donepezil},
keywords = {Plasma neuronal-derived extracellular vesicles},
keywords = {Tau},
title = {Modulation of Amyloid-beta and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin (R) and Donepezil},
doi = {10.3233/JAD-220575},
author = {Antón Álvarez, X. and Aleixandre Rico, Manuel},
}